Jennifer Desimone is a Dermatology physician affiliated with Inova Fairfax Hospital. OpenAlex indexes 46 publications with 1,063 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8081 Innovation Park Dr
Fairfax, VA 220314867
Telephone
571-472-4724Provider last certified this registry record 29 Dec 2021.
Clinical trials
- Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients
Sponsor: Inova Health Care Services
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Helsinn Therapeutics (U.S.), Inc.Program year20254 payments
- KYOWA KIRIN, INC.Program year20251 payment
- Krystal Biotech IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
34.9%Corticosteroid14.9%Triamcinolone Acetonide100%Part D≥20 patientsRetinoid12.9%Acitretin100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
33.7%Alkylating Drug15.7%Valchlor100%Part D≥11 patientsRetinoid12%Bexarotene100%Part D<11 patients+ 1 more class in this area
Anti-infectives
9.6%Azole Antifungal5.2%Ketoconazole100%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.4%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Topical combined 5-fluorouracil and calcipotriene for actinic keratosis and superficial keratinocyte carcinoma: Modified Delphi expert panel recommendations from ITSCC
Journal of the American Academy of Dermatology
2026 - Intralesional Cemiplimab for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma: Results From a Phase 1 Pilot Study Expansion Cohort
SKIN The Journal of Cutaneous Medicine
2026 - ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome
Journal of the American Academy of Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Nathan, MD
Inova Fairfax Hospital
William Ershler, MD
Inova Fairfax Hospital
Hannah Donovan, MD
Inova Fairfax Hospital
Ramani Balu, MD
Inova Fairfax Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”